Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis

In Vivo. 2020 May-Jun;34(3):1547-1553. doi: 10.21873/invivo.11944.

Abstract

Background/aim: Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancer patients with local recurrence.

Patients and methods: Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer.

Results: All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred close to the bowel in 6 patients. The 1-year and 2-year overall survival rates were 100% and 76.2% each; while the 1-year and 2-year metastasis free survival rates were 64.3% and 43%.

Conclusion: CIRT as re-irradiation for locally recurrent rectal cancer emerges as a safe and valid treatment with an acceptable rate of morbidity of surrounding healthy tissue.

Keywords: Rectal cancer recurrence; carbon ion radiotherapy; re-irradiation.

MeSH terms

  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Heavy Ion Radiotherapy* / adverse effects
  • Heavy Ion Radiotherapy* / methods
  • Humans
  • Kaplan-Meier Estimate
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Pelvis / diagnostic imaging
  • Pelvis / pathology*
  • Prognosis
  • Re-Irradiation*
  • Rectal Neoplasms / diagnostic imaging
  • Rectal Neoplasms / mortality
  • Rectal Neoplasms / pathology*
  • Rectal Neoplasms / radiotherapy*
  • Tomography, X-Ray Computed
  • Treatment Outcome